Acorda Therapeutics: PharmaVitae Report

NEW YORK, June 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Acorda Therapeutics: PharmaVitae Report
http://www.reportlinker.com/p0885024/Acorda-Therapeutics-PharmaVitae-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug. Gain insight into Acorda Therapeutics' strategic outlook Analyze company sales forecasts by product Acorda obtained rights to its lead product, Ampyra, in 2003. In January 2010, the FDA approved the drug to improve walking in patients with MS. Acorda recorded $211m in Ampyra sales in 2011 and it is also being developed to improve walking in patients with cerebral palsy and those with chronic debilitation from a stroke. Benchmark Acorda Therapeutics' performance against key rivals in the prescription pharmaceutical sector. See how, following Zanaflex's patent expiry, Acorda will become increasingly dependent on Ampyra's sales

ABOUT THIS REPORT-PharmaVitae Explorer database
-Chapter structure - Sales and product analysis
- Financial analysis

-Data sourcing - Analyst consensus

EXECUTIVE SUMMARY-Company introduction - Recent developments
- Corporate relationships

-Strategic overview
-SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats

SALES AND PRODUCT ANALYSIS-Sales overview
-Product analysis - Product sales

-Ampyra (dalfampridine) - Ampyra clinical trials in multiple sclerosis
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Ampyra shows significant effects, but only in a third of patients
- Seizure risk necessitates REMS program
- Ampyra is a useful drug for multiple sclerosis, but payers are likely to restrict uptake due to its high price
- Marketing of Ampyra has been successful to date

-Zanaflex (tizanidine hydrochloride)
-Diazepam nasal spray (DZNS)
-Early-stage products - GGF-2
- Chondroitinase

FINANCIAL ANALYSIS-Financial performance overview - Operating costs and profit analysis, 2005–11
- Operating costs and profit analysis, 2011–17

APPENDIX-References
-Exchange rates

TABLES-Table: Acorda R&D pipeline
-Table: Acorda key catalysts
-Table: Acorda product portfolio overview ($m), 2011–17
-Table: Overview of pivotal trial data for Ampyra, 2011
-Table: Ampyra ongoing trials
-Table: Datamonitor drug assessment summary of Ampyra for multiple sclerosis, 2011
-Table: Acorda operating revenue/cost analysis ($m), 2005–11
-Table: Acorda operating revenue/cost analysis ($m), 2011–17
-Table: Exchange rates, 2011

FIGURES-Figure: PharmaVitae Explorer
-Figure: Acorda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011–17
-Figure: Acorda product sales ($m), 2011–17
-Figure: Ampyra SWOT analysis in multiple sclerosis, 2011
-Figure: Datamonitor drug assessment summary of Ampyra for multiple sclerosis, 2011
-Figure: Acorda operating/cost performance ($m), 2004–16

Companies mentioned

Arriva plc, Hutchison 3G UK Limited, Schindler Holding Ltd., Telindus Group NV

To order this report:
: Acorda Therapeutics: PharmaVitae Report

Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker